niacinamide has been researched along with Sensitivity and Specificity in 70 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the volumetric iodine-uptake (VIU) changes by dual-energy CT (DECT) in assessing the response to sorafenib treated hepatocellular carcinoma (HCC) patients, compared with AASLD (American Association for the Study of Liver Diseases) and Choi criteria." | 9.17 | Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Dai, X; Ganten, MK; Ganten, TM; Höh, K; Schlemmer, HP; Schmidt, B; Xu, K, 2013) |
| "To evaluate the sonographic changes observed in hepatocellular carcinoma (HCC) post antiangiogenic treatment with sorafenib." | 9.16 | Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. ( Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K, 2012) |
| "To investigate the effectiveness of intravoxel incoherent motion (IVIM) in the assessment of the therapeutic efficacy of sorafenib in an orthotopic hepatocellular carcinoma (HCC) xenograft model." | 7.85 | Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model. ( Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH, 2017) |
| "To investigate the value of multiparametric magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) for monitoring the ultra-early (within 24 hours) treatment effect of sorafenib in human hepatocellular carcinoma (HCC) xenografts." | 7.85 | Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts. ( Chen, X; He, L; Huang, Y; Liang, C; Liu, Z; Ma, Z; Shi, C; Zhang, Z, 2017) |
| "To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM)." | 7.83 | Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study. ( Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K, 2016) |
| "To determine the total Apparent Diffusion Coefficient (ADC), the pure Diffusion coefficient (D) and the perfusion fraction (f) in advanced hepatocellular carcinoma (HCC) under sorafenib treatment." | 7.77 | The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. ( Arrivé, L; Fartoux, L; Lewin, M; Menu, Y; Rosmorduc, O; Vignaud, A, 2011) |
| "The objective of our study was to evaluate signal changes of advanced hepatocellular carcinoma in diffusion-weighted MRI in the early-response monitoring of oral therapy with the multikinase inhibitor sorafenib." | 7.75 | Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. ( Bitzer, M; Claussen, CD; Horger, M; Lauer, U; Martirosian, P; Schraml, C; Schwenzer, NF, 2009) |
| "placebo in hepatocellular carcinoma (HCC) demonstrated that sorafenib significantly prolonged overall survival (OS) compared to placebo." | 6.73 | Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. ( Carroll, S; Dale, P; Knox, J; Maroun, J; McDonald, H; Muszbek, N; Shah, S, 2008) |
| " The aim of the study was to assess the predictive value of early metabolic response (mR) evaluation after one cycle, and its interlesional heterogeneity to a later metabolic and morphological response assessment performed after three cycles in metastatic colorectal cancer (mCRC) patients treated with combined sorafenib and capecitabine." | 5.22 | Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. ( Ameye, L; Delaunoit, T; Deleporte, A; Demolin, G; Flamen, P; Garcia, C; Gauthier, N; Guiot, T; Hendlisz, A; Holbrechts, S; Lhommel, R; Maréchal, R; Van den Eynde, M; Vierasu, I; Woff, E, 2016) |
| "To investigate the volumetric iodine-uptake (VIU) changes by dual-energy CT (DECT) in assessing the response to sorafenib treated hepatocellular carcinoma (HCC) patients, compared with AASLD (American Association for the Study of Liver Diseases) and Choi criteria." | 5.17 | Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Dai, X; Ganten, MK; Ganten, TM; Höh, K; Schlemmer, HP; Schmidt, B; Xu, K, 2013) |
| "To evaluate the sonographic changes observed in hepatocellular carcinoma (HCC) post antiangiogenic treatment with sorafenib." | 5.16 | Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. ( Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K, 2012) |
| "To investigate the effectiveness of intravoxel incoherent motion (IVIM) in the assessment of the therapeutic efficacy of sorafenib in an orthotopic hepatocellular carcinoma (HCC) xenograft model." | 3.85 | Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model. ( Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH, 2017) |
| "To investigate the value of multiparametric magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) for monitoring the ultra-early (within 24 hours) treatment effect of sorafenib in human hepatocellular carcinoma (HCC) xenografts." | 3.85 | Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts. ( Chen, X; He, L; Huang, Y; Liang, C; Liu, Z; Ma, Z; Shi, C; Zhang, Z, 2017) |
| "To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM)." | 3.83 | Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study. ( Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K, 2016) |
| "To determine the total Apparent Diffusion Coefficient (ADC), the pure Diffusion coefficient (D) and the perfusion fraction (f) in advanced hepatocellular carcinoma (HCC) under sorafenib treatment." | 3.77 | The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. ( Arrivé, L; Fartoux, L; Lewin, M; Menu, Y; Rosmorduc, O; Vignaud, A, 2011) |
| "Sorafenib is recommended for therapy of advanced hepatocellular carcinoma and renal cell carcinoma." | 3.77 | High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. ( Heinz, WJ; Helle-Beyersdorf, A; Kahle, K; Keller, D; Klinker, H; Langmann, P; Lenker, U; Schirmer, D, 2011) |
| "The objective of our study was to evaluate signal changes of advanced hepatocellular carcinoma in diffusion-weighted MRI in the early-response monitoring of oral therapy with the multikinase inhibitor sorafenib." | 3.75 | Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. ( Bitzer, M; Claussen, CD; Horger, M; Lauer, U; Martirosian, P; Schraml, C; Schwenzer, NF, 2009) |
| " We could show variability in plasma levels according to changes in dosage of TKIs or during treatment-free intervals." | 2.80 | [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib]. ( Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P, 2015) |
| " The method was sensitive, specific, precise, accurate and suitable for bioequivalence and pharmacokinetic studies." | 2.75 | Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ( Damaramadugu, R; Inamadugu, JK; Mullangi, R; Ponneri, V, 2010) |
| "placebo in hepatocellular carcinoma (HCC) demonstrated that sorafenib significantly prolonged overall survival (OS) compared to placebo." | 2.73 | Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. ( Carroll, S; Dale, P; Knox, J; Maroun, J; McDonald, H; Muszbek, N; Shah, S, 2008) |
| "Sorafenib is a targeted drug approved for metastatic renal cell carcinoma but it has modest efficacy." | 1.39 | Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. ( Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ, 2013) |
| "In sorafenib-treated tumors, significantly more apoptotic cells (TUNEL; 7132 ± 3141 vs." | 1.38 | Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. ( Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Eschbach, R; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; von Einem, JC; Wintersperger, BJ, 2012) |
| "Procainamide was used as an internal standard (IS)." | 1.37 | Simultaneous quantitation of nicorandil and its denitrated metabolite in plasma by LC-MS/MS: application for a pharmacokinetic study. ( Araujo, DP; Bastos, LF; César, IC; Coelho, Mde M; de Fátima, Â; Godin, AM; Guidine, PA; Pianetti, GA, 2011) |
| "Myristyl nicotinate (Nia-114) is an ester prodrug being developed for delivery of nicotinic acid (NIC) into the skin for prevention of actinic keratosis and its progression to skin cancer." | 1.33 | Simultaneous determination of myristyl nicotinate, nicotinic acid, and nicotinamide in rabbit plasma by liquid chromatography-tandem mass spectrometry using methyl ethyl ketone as a deproteinization solvent. ( Catz, P; Green, CE; Jacobson, EL; Jacobson, MK; Kapetanovic, IM; Kim, H; Kim, M; Shinn, W, 2005) |
| " Thus, this method has been validated and can be applied for the drug monitoring or pharmacokinetic studies of BAY 43-9006 in small volumes of serum samples." | 1.32 | Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum. ( Afify, S; Högger, P; Rapp, UR, 2004) |
| "Pimonidazole was used as a marker of hypoxia and was analyzed with a digital image processing system." | 1.31 | Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescense based fiber-optic probes. ( Bussink, J; Kaanders, JH; Strik, AM; van der Kogel, AJ, 2000) |
| "N1-Methylnicotinamide (NMN) is an endogenous cationic metabolite of nicotinamide (niacine, vitamine PP) whose renal clearance reflects both the capacity of the renal tubular transport system to secrete organic cations and renal plasma flow." | 1.31 | Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow. ( Bélaz, N; Biollaz, J; Decosterd, LA; Kesselring, UW; Musfeld, C, 2001) |
| "We used the human hypopharyngeal squamous cell carcinoma cell line FaDu implanted in immune-deficient SCID mice and assessed its response to radiation by cell survival and by growth delay." | 1.30 | Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation. ( Brown, JM; Dorie, MJ; el-Said, A; Menke, D, 1999) |
| " The method is based on solid phase extraction in combination with ion-paired reversed phase high performance liquid chromatography." | 1.29 | Simultaneous determination of nicotinic acid and its two metabolites in human plasma using solid-phase extraction in combination with high performance liquid chromatography. ( Miyauchi, Y; Nakamura, T; Sano, N, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (8.57) | 18.2507 |
| 2000's | 22 (31.43) | 29.6817 |
| 2010's | 39 (55.71) | 24.3611 |
| 2020's | 3 (4.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, GR | 1 |
| Shah, I | 1 |
| Gariballa, S | 1 |
| Yasin, J | 1 |
| Barker, J | 1 |
| Salman Ashraf, S | 1 |
| Li, R | 1 |
| Ren, M | 1 |
| Lu, W | 1 |
| Yuan, Y | 1 |
| Li, J | 1 |
| Zhong, W | 1 |
| Blasco, H | 1 |
| Bessy, C | 1 |
| Plantier, L | 1 |
| Lefevre, A | 1 |
| Piver, E | 1 |
| Bernard, L | 1 |
| Marlet, J | 1 |
| Stefic, K | 1 |
| Benz-de Bretagne, I | 1 |
| Cannet, P | 1 |
| Lumbu, H | 1 |
| Morel, T | 1 |
| Boulard, P | 1 |
| Andres, CR | 1 |
| Vourc'h, P | 1 |
| Hérault, O | 1 |
| Guillon, A | 1 |
| Emond, P | 1 |
| Allard, M | 1 |
| Khoudour, N | 1 |
| Rousseau, B | 1 |
| Joly, C | 1 |
| Costentin, C | 1 |
| Blanchet, B | 1 |
| Tournigand, C | 1 |
| Hulin, A | 1 |
| Paddubny, K | 2 |
| Freitag, MT | 1 |
| Kratochwil, C | 2 |
| Koerber, S | 1 |
| Radtke, JP | 2 |
| Sakovich, R | 1 |
| Kopka, K | 2 |
| Giesel, FL | 2 |
| Will, L | 1 |
| Kremer, C | 1 |
| Rathke, H | 1 |
| Haufe, S | 1 |
| Haberkorn, U | 1 |
| Fan, B | 1 |
| You, J | 1 |
| Suo, Y | 1 |
| Qian, C | 1 |
| Ladep, NG | 1 |
| Dona, AC | 1 |
| Lewis, MR | 1 |
| Crossey, MM | 1 |
| Lemoine, M | 1 |
| Okeke, E | 1 |
| Shimakawa, Y | 1 |
| Duguru, M | 1 |
| Njai, HF | 1 |
| Fye, HK | 1 |
| Taal, M | 1 |
| Chetwood, J | 1 |
| Kasstan, B | 1 |
| Khan, SA | 1 |
| Garside, DA | 1 |
| Wijeyesekera, A | 1 |
| Thillainayagam, AV | 1 |
| Banwat, E | 1 |
| Thursz, MR | 1 |
| Nicholson, JK | 1 |
| Njie, R | 1 |
| Holmes, E | 1 |
| Taylor-Robinson, SD | 1 |
| Yu, HJ | 1 |
| Shin, JA | 1 |
| Jung, JY | 1 |
| Nam, JS | 1 |
| Hong, IS | 1 |
| Cho, NP | 1 |
| Cho, SD | 1 |
| Nobuoka, Y | 1 |
| Ogawa, R | 1 |
| Echizen, H | 1 |
| Oda, K | 1 |
| Mera, K | 1 |
| Nagasaka, Y | 1 |
| Tokoro, K | 1 |
| Keil, C | 1 |
| Götze, L | 1 |
| Olbert, P | 1 |
| Hofmann, R | 1 |
| Nockher, WA | 1 |
| Hegele, A | 1 |
| Jeon, TY | 1 |
| Kim, CK | 1 |
| Kim, JH | 1 |
| Im, GH | 1 |
| Park, BK | 1 |
| Lee, JH | 1 |
| Gariani, K | 1 |
| Menzies, KJ | 1 |
| Ryu, D | 1 |
| Wegner, CJ | 1 |
| Wang, X | 1 |
| Ropelle, ER | 1 |
| Moullan, N | 1 |
| Zhang, H | 1 |
| Perino, A | 1 |
| Lemos, V | 1 |
| Kim, B | 1 |
| Park, YK | 1 |
| Piersigilli, A | 1 |
| Pham, TX | 1 |
| Yang, Y | 1 |
| Ku, CS | 1 |
| Koo, SI | 1 |
| Fomitchova, A | 1 |
| Cantó, C | 1 |
| Schoonjans, K | 1 |
| Sauve, AA | 1 |
| Lee, JY | 1 |
| Auwerx, J | 1 |
| Shirota, N | 1 |
| Saito, K | 1 |
| Sugimoto, K | 1 |
| Takara, K | 1 |
| Moriyasu, F | 1 |
| Tokuuye, K | 1 |
| Zhiliang, L | 1 |
| Peiying, J | 1 |
| Suying, F | 1 |
| Woff, E | 1 |
| Hendlisz, A | 1 |
| Garcia, C | 1 |
| Deleporte, A | 1 |
| Delaunoit, T | 1 |
| Maréchal, R | 1 |
| Holbrechts, S | 1 |
| Van den Eynde, M | 1 |
| Demolin, G | 1 |
| Vierasu, I | 1 |
| Lhommel, R | 1 |
| Gauthier, N | 1 |
| Guiot, T | 1 |
| Ameye, L | 1 |
| Flamen, P | 1 |
| Yang, SH | 1 |
| Lin, J | 1 |
| Lu, F | 1 |
| Han, ZH | 1 |
| Fu, CX | 1 |
| Lv, P | 1 |
| Liu, H | 1 |
| Gao, DM | 1 |
| Chen, X | 1 |
| Ma, Z | 1 |
| Huang, Y | 1 |
| He, L | 1 |
| Liang, C | 2 |
| Shi, C | 1 |
| Zhang, Z | 1 |
| Liu, Z | 1 |
| Mukherjee, S | 1 |
| Chellappa, K | 1 |
| Moffitt, A | 1 |
| Ndungu, J | 1 |
| Dellinger, RW | 1 |
| Davis, JG | 1 |
| Agarwal, B | 1 |
| Baur, JA | 1 |
| Adjei, AA | 1 |
| Muszbek, N | 1 |
| Shah, S | 1 |
| Carroll, S | 1 |
| McDonald, H | 1 |
| Dale, P | 1 |
| Maroun, J | 1 |
| Knox, J | 1 |
| Sparidans, RW | 1 |
| Vlaming, ML | 1 |
| Lagas, JS | 1 |
| Schinkel, AH | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Adams, RW | 1 |
| Aguilar, JA | 1 |
| Atkinson, KD | 1 |
| Cowley, MJ | 1 |
| Elliott, PI | 1 |
| Duckett, SB | 1 |
| Green, GG | 1 |
| Khazal, IG | 1 |
| López-Serrano, J | 1 |
| Williamson, DC | 1 |
| Liu, X | 1 |
| Dong, F | 1 |
| Qin, D | 1 |
| Zheng, Y | 1 |
| Jilaveanu, LB | 1 |
| Zito, CR | 1 |
| Aziz, SA | 1 |
| Conrad, PJ | 1 |
| Schmitz, JC | 1 |
| Sznol, M | 1 |
| Camp, RL | 1 |
| Rimm, DL | 1 |
| Kluger, HM | 1 |
| Schraml, C | 2 |
| Schwenzer, NF | 1 |
| Martirosian, P | 1 |
| Bitzer, M | 2 |
| Lauer, U | 1 |
| Claussen, CD | 2 |
| Horger, M | 2 |
| Maksimovic, O | 1 |
| Hartmann, JT | 1 |
| Pintoffl, J | 1 |
| Smith, AD | 2 |
| Lieber, ML | 2 |
| Shah, SN | 2 |
| Kudo, M | 1 |
| Rini, BI | 1 |
| Remer, EM | 1 |
| Akisik, MF | 1 |
| Sandrasegaran, K | 1 |
| Bu, G | 1 |
| Lin, C | 1 |
| Hutchins, GD | 1 |
| Chiorean, EG | 1 |
| Fournier, LS | 1 |
| Oudard, S | 1 |
| Thiam, R | 1 |
| Trinquart, L | 1 |
| Banu, E | 1 |
| Medioni, J | 1 |
| Balvay, D | 1 |
| Chatellier, G | 1 |
| Frija, G | 1 |
| Cuenod, CA | 1 |
| Mirabal, NC | 1 |
| Yzquierdo, SL | 1 |
| Lemus, D | 1 |
| Madruga, M | 1 |
| Milián, Y | 1 |
| Echemendía, M | 1 |
| Takiff, H | 2 |
| Martin, A | 2 |
| Van der Stuyf, P | 1 |
| Palomino, JC | 2 |
| Montoro, E | 1 |
| Lind, JS | 1 |
| Meijerink, MR | 1 |
| Dingemans, AM | 1 |
| van Kuijk, C | 1 |
| Ollers, MC | 1 |
| de Ruysscher, D | 1 |
| Postmus, PE | 1 |
| Smit, EF | 1 |
| Lewin, M | 1 |
| Fartoux, L | 1 |
| Vignaud, A | 1 |
| Arrivé, L | 1 |
| Menu, Y | 1 |
| Rosmorduc, O | 1 |
| Inamadugu, JK | 1 |
| Damaramadugu, R | 1 |
| Mullangi, R | 1 |
| Ponneri, V | 1 |
| Heinz, WJ | 1 |
| Kahle, K | 1 |
| Helle-Beyersdorf, A | 1 |
| Schirmer, D | 1 |
| Lenker, U | 1 |
| Keller, D | 1 |
| Langmann, P | 1 |
| Klinker, H | 1 |
| Cyran, CC | 1 |
| von Einem, JC | 1 |
| Paprottka, PM | 1 |
| Schwarz, B | 1 |
| Ingrisch, M | 1 |
| Dietrich, O | 1 |
| Hinkel, R | 1 |
| Bruns, CJ | 1 |
| Clevert, DA | 1 |
| Eschbach, R | 1 |
| Reiser, MF | 1 |
| Wintersperger, BJ | 1 |
| Nikolaou, K | 1 |
| César, IC | 1 |
| Bastos, LF | 1 |
| Godin, AM | 1 |
| Coelho, Mde M | 1 |
| Araujo, DP | 1 |
| de Fátima, Â | 1 |
| Guidine, PA | 1 |
| Pianetti, GA | 1 |
| Logan, J | 1 |
| Carruthers, NI | 1 |
| Letavic, MA | 1 |
| Sands, S | 1 |
| Jiang, X | 1 |
| Shea, C | 1 |
| Muench, L | 1 |
| Xu, Y | 1 |
| Carter, P | 1 |
| King, P | 1 |
| Fowler, JS | 1 |
| Moschouris, H | 1 |
| Malagari, K | 1 |
| Gkoutzios, P | 1 |
| Kalokairinou, M | 1 |
| Stamatiou, K | 1 |
| Chatzimichail, K | 1 |
| Kornezos, I | 1 |
| Karagiannis, E | 1 |
| Kiltenis, M | 1 |
| Papadaki, MG | 1 |
| Jin, P | 1 |
| Xia, L | 1 |
| Li, Z | 1 |
| Che, N | 1 |
| Zou, D | 1 |
| Hu, X | 1 |
| Suzuki, Y | 1 |
| Nakamura, Y | 1 |
| Yamada, K | 2 |
| Huber, VJ | 1 |
| Tsujita, M | 1 |
| Nakada, T | 1 |
| Hampel, D | 1 |
| York, ER | 1 |
| Allen, LH | 1 |
| Benitez, A | 1 |
| Yates, TJ | 1 |
| Shamaldevi, N | 1 |
| Bowen, T | 1 |
| Lokeshwar, VB | 1 |
| Dai, X | 1 |
| Schlemmer, HP | 1 |
| Schmidt, B | 1 |
| Höh, K | 1 |
| Xu, K | 1 |
| Ganten, TM | 1 |
| Ganten, MK | 1 |
| Frampas, E | 1 |
| Lassau, N | 1 |
| Zappa, M | 1 |
| Vullierme, MP | 1 |
| Koscielny, S | 1 |
| Vilgrain, V | 1 |
| Afify, S | 1 |
| Rapp, UR | 1 |
| Högger, P | 1 |
| Baudelet, C | 1 |
| Ansiaux, R | 1 |
| Jordan, BF | 1 |
| Havaux, X | 1 |
| Macq, B | 1 |
| Gallez, B | 1 |
| Creeke, PI | 2 |
| Seal, AJ | 2 |
| Beeram, M | 1 |
| Patnaik, A | 1 |
| Rowinsky, EK | 1 |
| Catz, P | 1 |
| Shinn, W | 1 |
| Kapetanovic, IM | 1 |
| Kim, H | 1 |
| Kim, M | 1 |
| Jacobson, EL | 1 |
| Jacobson, MK | 1 |
| Green, CE | 1 |
| Hara, N | 1 |
| Shibata, T | 1 |
| Osago, H | 1 |
| Tsuchiya, M | 1 |
| Hug, B | 1 |
| Golay, PA | 1 |
| Giuffrida, F | 1 |
| Dionisi, F | 1 |
| Destaillats, F | 1 |
| Vandamme, P | 1 |
| Swings, J | 1 |
| Portaels, F | 1 |
| Zhao, M | 1 |
| Rudek, MA | 1 |
| He, P | 1 |
| Hafner, FT | 1 |
| Radtke, M | 1 |
| Wright, JJ | 1 |
| Smith, BD | 1 |
| Messersmith, WA | 1 |
| Hidalgo, M | 1 |
| Baker, SD | 1 |
| Dibari, F | 1 |
| Cheung, E | 1 |
| van den Briel, T | 1 |
| Kyroussis, E | 1 |
| Day, IJ | 1 |
| Mitchell, JC | 1 |
| Snowden, MJ | 1 |
| Davis, AL | 1 |
| Jain, L | 1 |
| Gardner, ER | 1 |
| Venitz, J | 1 |
| Dahut, W | 1 |
| Figg, WD | 1 |
| Stein, J | 1 |
| Hahn, A | 1 |
| Rehner, G | 1 |
| Miyauchi, Y | 1 |
| Sano, N | 1 |
| Nakamura, T | 1 |
| Thomas, CD | 1 |
| Stern, S | 1 |
| Chaplin, DJ | 1 |
| Guichard, M | 1 |
| Fotsing, L | 1 |
| Fillet, M | 1 |
| Bechet, I | 1 |
| Hubert, P | 1 |
| Crommen, J | 1 |
| el-Said, A | 1 |
| Menke, D | 1 |
| Dorie, MJ | 1 |
| Brown, JM | 1 |
| Ruddock, MW | 1 |
| Burns, DM | 1 |
| Murphy, LE | 1 |
| O'Rourke, MG | 1 |
| Hirst, DG | 1 |
| Bussink, J | 1 |
| Kaanders, JH | 1 |
| Strik, AM | 1 |
| van der Kogel, AJ | 1 |
| Long, Y | 1 |
| Li, W | 1 |
| Nie, L | 1 |
| Yao, S | 1 |
| Musfeld, C | 1 |
| Biollaz, J | 1 |
| Bélaz, N | 1 |
| Kesselring, UW | 1 |
| Decosterd, LA | 1 |
| Holzmann, S | 1 |
| Kukovetz, WR | 1 |
| Braida, C | 1 |
| Pöch, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Regorafenib in Patients With Refractory Primary Bone Tumors[NCT05395741] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2022-04-28 | Recruiting | ||
| Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone: a Multi-center Retrospective Study for Standardization and Modification of Response Evaluation Criteria[NCT03742063] | 190 participants (Actual) | Observational | 2017-06-01 | Completed | |||
| Multiomics Approach for Patients Stratification and Novel Target Identification in Metastatic Clear Renal Cell Carcnoma[NCT05782400] | 100 participants (Anticipated) | Observational | 2023-02-28 | Recruiting | |||
| Establishing a Correlation Between Pre-treatment CT Perfusion Parameter Values and Post-treatment PET/CT Dosimetry to Aid in Tumor-specific Y-90 Radioembolization Treatment Planning for Hepatocellular Carcinoma[NCT02558205] | 0 participants (Actual) | Observational | 2015-07-31 | Withdrawn (stopped due to unable to rectuir) | |||
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer[NCT00090545] | Phase 2 | 46 participants (Actual) | Interventional | 2004-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Geometric mean exposure for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | mg/L.h (Geometric Mean) |
|---|---|
| First Stage - Disease Progression | 9.76 |
| Second Stage - Increased Accrual | 18.63 |
Plasma concentration-time profile for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, AND 24 hours post dose
| Intervention | mg/L (Mean) |
|---|---|
| First Stage - Disease Progression | 1.28 |
| Second Stage - Increased Accrual | 2.57 |
Time from treatment start date until date of death or date last known alive. (NCT00090545)
Timeframe: Time from treatment start date until date of death or date last known alive, approximately 18.3 months.
| Intervention | Months (Median) |
|---|---|
| First Stage - Disease Progression | 18 |
| Second Stage - Increased Accrual | 18.3 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT00090545)
Timeframe: Date treatment consent signed to date off study, approximately 49 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| First Stage - Disease Progression | 22 |
| Second Stage - Increased Accrual | 23 |
Determine whether BAY 43-9006 when used to treat metastatic prostate cancer is associated with having 50% of Patients Progression Free at 4 Months by clinical, radiographic, and prostatic specific antigen (PSA)criteria. (NCT00090545)
Timeframe: 4 months
| Intervention | months (Median) |
|---|---|
| First Stage - Disease Progression | 1.83 |
| Second Stage - Increased Accrual | 3.7 |
Time to maximum concentration for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | hours (Median) |
|---|---|
| First Stage - Disease Progression | 0.68 |
| Second Stage - Increased Accrual | 8 |
Overall response was evaluated by the RECIST. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00090545)
Timeframe: Every 2 cycles (1 cycle = 28 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| First Stage - Disease Progression | 0 | 0 | 8 | 0 |
| Second Stage - Increased Accrual | 0 | 1 | 13 | 10 |
2 reviews available for niacinamide and Sensitivity and Specificity
| Article | Year |
|---|---|
K-ras as a target for lung cancer therapy.
Topics: Benzamides; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Cl | 2008 |
Raf: a strategic target for therapeutic development against cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Down-Regulation; Drug Delivery Systems; Humans; M | 2005 |
10 trials available for niacinamide and Sensitivity and Specificity
| Article | Year |
|---|---|
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility | 2015 |
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Dru | 2016 |
Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.
Topics: Antineoplastic Agents; Benzenesulfonates; Canada; Carcinoma, Hepatocellular; Disease-Free Survival; | 2008 |
Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Contrast Media; Female; Gad | 2010 |
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; F | 2010 |
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; C | 2010 |
Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Topics: Chromatography, Liquid; Drug Stability; Humans; Linear Models; Male; Nevirapine; Niacin; Niacinamide | 2010 |
Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Cont | 2012 |
Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; H | 2013 |
Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Med | 2013 |
58 other studies available for niacinamide and Sensitivity and Specificity
| Article | Year |
|---|---|
Significantly Elevated Levels of Plasma Nicotinamide, Pyridoxal, and Pyridoxamine Phosphate Levels in Obese Emirati Population: A Cross-Sectional Study.
Topics: Adolescent; Adult; Biomarkers; Chromatography, Liquid; Cross-Sectional Studies; Female; Humans; Male | 2020 |
A validated LC-MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat.
Topics: Administration, Intravenous; Administration, Oral; Animals; Biological Availability; Chromatography, | 2021 |
The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism.
Topics: Aged; Aged, 80 and over; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Cytosine; Ea | 2020 |
Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.
Topics: Chromatography, Liquid; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Reproducibility of Res | 2017 |
Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy.
Topics: Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; N | 2018 |
[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty.
Topics: Arthroplasty; Fluorine Radioisotopes; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local | 2018 |
A novel and sensitive method for determining vitamin B3 and B7 by pre-column derivatization and high-performance liquid chromatography method with fluorescence detection.
Topics: Chromatography, High Pressure Liquid; Fluorescence; Limit of Detection; Niacinamide; Sensitivity and | 2018 |
Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans.
Topics: Acetylcarnitine; Adolescent; Adult; Africa, Western; Aged; Aged, 80 and over; alpha-Fetoproteins; Bi | 2014 |
Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Cell Proliferation; Disease Models | 2015 |
Simultaneous determination of N(1)-methylnicotinamide, L-carnitine, and creatinine in human plasma and urine by liquid chromatography with mass spectrometry for assessing the activities of multiple renal cationic transporters.
Topics: Carnitine; Chromatography, Liquid; Creatinine; Drug Stability; Female; Humans; Male; Mass Spectromet | 2014 |
Simultaneous determination of a novel oral Janus kinase inhibitor ASP015K and its sulfated metabolite in rat plasma using LC-MS/MS.
Topics: Adamantane; Administration, Oral; Animals; Chromatography, Liquid; Female; Janus Kinases; Linear Mod | 2015 |
Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Diffusion Magnetic Resonance Imag | 2015 |
Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice.
Topics: Analysis of Variance; Animals; Area Under Curve; Biopsy, Needle; Diet, High-Fat; Disease Models, Ani | 2016 |
Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Algorithms; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Diff | 2016 |
Diagnosis of pemphigoid nodularis with serological assay.
Topics: Administration, Cutaneous; Anti-Bacterial Agents; Biopsy; Drug Therapy, Combination; Enzyme-Linked I | 2016 |
Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor | 2017 |
Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Diffusion Magnetic Reso | 2017 |
Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration.
Topics: Animals; Disease Models, Animal; Fluorescent Antibody Technique; Hepatectomy; Immunoblotting; Immuno | 2017 |
Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Chromatography, Liquid; Female; Glucuronides; Liv | 2009 |
Reversible interactions with para-hydrogen enhance NMR sensitivity by polarization transfer.
Topics: Carbon; Hydrogen; Iridium; Ligands; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Nia | 2009 |
Residue analysis of kresoxim-methyl and boscalid in fruits, vegetables and soil using liquid-liquid extraction and gas chromatography-mass spectrometry.
Topics: Biphenyl Compounds; Chemical Fractionation; Fruit; Fungicides, Industrial; Gas Chromatography-Mass S | 2010 |
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; | 2009 |
Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, | 2009 |
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
Topics: Adrenal Gland Neoplasms; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; | 2010 |
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease | 2010 |
The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
Topics: Algorithms; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tu | 2010 |
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Dise | 2010 |
Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Colorimetry; Drug Resistance, Bacterial; Humans; Microbial S | 2010 |
The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diffusion Mag | 2011 |
High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.
Topics: Antineoplastic Agents; Ascitic Fluid; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal | 2011 |
Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Cell Line, Tumor; Contrast Media; Ioh | 2012 |
Simultaneous quantitation of nicorandil and its denitrated metabolite in plasma by LC-MS/MS: application for a pharmacokinetic study.
Topics: Animals; Chromatography, Liquid; Female; Male; Niacinamide; Nicorandil; Procainamide; Rats; Rats, Wi | 2011 |
Blockade of the brain histamine H3 receptor by JNJ-39220675: preclinical PET studies with [¹¹C]GSK189254 in anesthetized baboon.
Topics: Administration, Oral; Animals; Azepines; Benzazepines; Blood-Brain Barrier; Brain; Dose-Response Rel | 2012 |
Rapid determination of thiamine, riboflavin, niacinamide, pantothenic acid, pyridoxine, folic acid and ascorbic acid in Vitamins with Minerals Tablets by high-performance liquid chromatography with diode array detector.
Topics: Acetonitriles; Ammonium Hydroxide; Ascorbic Acid; Buffers; Calibration; Chromatography, High Pressur | 2012 |
Aquaporin-4 positron emission tomography imaging of the human brain: first report.
Topics: Adult; Animals; Aquaporin 4; Brain; Female; Humans; Male; Mice; Middle Aged; Niacinamide; Pilot Proj | 2013 |
Ultra-performance liquid chromatography tandem mass-spectrometry (UPLC-MS/MS) for the rapid, simultaneous analysis of thiamin, riboflavin, flavin adenine dinucleotide, nicotinamide and pyridoxal in human milk.
Topics: Chromatography, High Pressure Liquid; Humans; Linear Models; Milk, Human; Niacinamide; Pyridoxal; Re | 2012 |
Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dietary Supplements; Disease Models, | 2013 |
Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum.
Topics: Animals; Benzenesulfonates; Calibration; Enzyme Inhibitors; Mice; Niacinamide; Phenylurea Compounds; | 2004 |
Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia?
Topics: Animals; Biomarkers, Tumor; Carbon Dioxide; Cell Hypoxia; Cell Line, Tumor; Computer Simulation; Fib | 2004 |
Quantitation of the niacin metabolites 1-methylnicotinamide and l-methyl-2-pyridone-5-carboxamide in random spot urine samples, by ion-pairing reverse-phase HPLC with UV detection, and the implications for the use of spot urine samples in the assessment o
Topics: Chromatography, High Pressure Liquid; Niacin; Niacinamide; Pyridones; Reproducibility of Results; Se | 2005 |
Simultaneous determination of myristyl nicotinate, nicotinic acid, and nicotinamide in rabbit plasma by liquid chromatography-tandem mass spectrometry using methyl ethyl ketone as a deproteinization solvent.
Topics: Animals; Butanones; Chromatography, Liquid; Niacin; Niacinamide; Rabbits; Reference Standards; Repro | 2005 |
The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry.
Topics: Adenosine Diphosphate Ribose; Adenosine Monophosphate; Animals; Chromatography, Liquid; Erythrocytes | 2006 |
Development of a gas-liquid chromatographic method for the analysis of fatty acid tryptamides in cocoa products.
Topics: Cacao; Chromatography, Gas; Fatty Acids; Niacinamide; Reproducibility of Results; Seeds; Sensitivity | 2006 |
A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide.
Topics: Amidohydrolases; Antitubercular Agents; Colorimetry; DNA, Bacterial; Drug Resistance, Bacterial; Fal | 2006 |
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
Topics: Area Under Curve; Benzenesulfonates; Calibration; Niacinamide; Phenylurea Compounds; Protein Kinase | 2007 |
Whole blood NAD and NADP concentrations are not depressed in subjects with clinical pellagra.
Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; NAD; NADP; Niacinamide; Pellagra; Pyridones; S | 2007 |
Co-acquisition of hyperpolarised 13C and 15N NMR spectra.
Topics: Carbon Isotopes; Free Radicals; Microwaves; Niacinamide; Nitrogen Isotopes; Nuclear Magnetic Resonan | 2007 |
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
Topics: Benzenesulfonates; Calibration; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors | 2008 |
High-performance liquid chromatographic determination of nicotinic acid and nicotinamide in biological samples applying post-column derivatization resulting in bathmochrome absorption shifts.
Topics: Animals; Chromatography, High Pressure Liquid; Intestines; Male; Niacin; Niacinamide; Rats; Rats, Wi | 1995 |
Simultaneous determination of nicotinic acid and its two metabolites in human plasma using solid-phase extraction in combination with high performance liquid chromatography.
Topics: Adult; Chromatography, High Pressure Liquid; Humans; Male; Niacin; Niacinamide; Nicotinic Acids; Rep | 1993 |
Transient perfusion and radiosensitizing effect after nicotinamide, carbogen, and perflubron emulsion administration.
Topics: Adenocarcinoma; Animals; Carbon Dioxide; Emulsions; Female; Fluorocarbons; Humans; Hydrocarbons, Bro | 1996 |
Determination of six water-soluble vitamins in a pharmaceutical formulation by capillary electrophoresis.
Topics: Ascorbic Acid; Drug Combinations; Electrophoresis, Capillary; Niacinamide; Pantothenic Acid; Pyridox | 1997 |
Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
Topics: Animals; Carbon Dioxide; Carcinoma, Squamous Cell; Cell Survival; Chemotherapy, Adjuvant; Combined M | 1999 |
The effect of nicotinamide on spontaneous and induced activity in smooth and skeletal muscle.
Topics: Animals; Anura; Culture Techniques; Dose-Response Relationship, Drug; Gastrointestinal Motility; Ile | 2000 |
Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescense based fiber-optic probes.
Topics: Analysis of Variance; Animals; Carbon Dioxide; Cell Hypoxia; Disease Models, Animal; Fiber Optic Tec | 2000 |
Ion-selective piezoelectric sensor for niacinamide assay in serum and urine.
Topics: Electrodes; Hydrogen-Ion Concentration; Niacinamide; Sensitivity and Specificity | 2001 |
Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow.
Topics: Biomarkers; Calibration; Cations; Chromatography, High Pressure Liquid; Humans; Ion Transport; Kidne | 2001 |
Pharmacological interaction experiments differentiate between glibenclamide-sensitive K+ channels and cyclic GMP as components of vasodilation by nicorandil.
Topics: Animals; Benzopyrans; Cattle; Coronary Vessels; Cromakalim; Cyclic GMP; Drug Interactions; Glyburide | 1992 |